Last reviewed · How we verify
ARQ 501
ARQ 501 is a selective inhibitor of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase.
ARQ 501 is a selective inhibitor of the anaplastic lymphoma kinase (ALK) receptor tyrosine kinase. Used for Non-small cell lung cancer with ALK rearrangement.
At a glance
| Generic name | ARQ 501 |
|---|---|
| Sponsor | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) |
| Drug class | ALK inhibitor |
| Target | ALK |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
ALK inhibitors, such as ARQ 501, target the ALK protein, which is involved in the development and progression of certain types of cancer. By inhibiting ALK, ARQ 501 aims to slow or stop the growth of cancer cells.
Approved indications
- Non-small cell lung cancer with ALK rearrangement
Common side effects
- Diarrhea
- Nausea
- Vomiting
Key clinical trials
- ARQ-761 Treatment With Gemcitabine/Nab-Paclitaxel Chemotherapy In Pancreatic Cancer (PHASE1)
- Clinical Trial of ARQ 761 in Advanced Solid Tumors (PHASE1)
- ARQ761 + PARP Inhibitor in Refractory Solid Tumors (PHASE1)
- Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers (PHASE1)
- Therapeutic Exploratory Phase 2 Study to Evaluate the Safety and Efficacy of MB12066 in Patients With Nonalcoholic Fatty Liver Disease(NAFLD) Except Cirrhosis (PHASE2)
- Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Male Volunteers (PHASE1)
- Safety, Tolerability and Pharmacokinetic Study of MB12066 in Healthy Volunteers (PHASE1)
- An Extension Study for Patients Previously Treated With ARQ 501 (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: